Dr. Wang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
700 E Morehead St
Charlotte, NC 28202Phone+1 704-334-7800Fax+1 704-414-7512
Education & Training
Johns Hopkins UniversityFellowship, Vascular and Interventional Radiology, 2004 - 2005
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Radiology-Diagnostic, 2000 - 2004
New York Presbyterian HospitalInternship, Transitional Year, 1999 - 2000- Johns Hopkins University School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2001 - Present
NC State Medical License 2005 - 2025
SC State Medical License 2005 - 2025
MD State Medical License 2004 - 2005- American Board of Radiology Interventional Radiology and Diagnostic Radiology
Clinical Trials
- FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 1 citationsOverall survival and toxicity of hepatocellular carcinoma Barcelona Clinic Liver Cancer B patients receiving Y90 radioembolization: analysis of the radiation-emitting ...Oladapo R Adeniran, Christian N Nguyen, Thomas H Perez, Shelby K Frantz, Lea Matsuoka
Journal of Gastrointestinal Oncology. 2023-04-29 - 5 citationsSurvival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry.Taylor J Robinson, Liping Du, Lea Matsuoka, Daniel Y Sze, Andrew S Kennedy
Journal of Vascular and Interventional Radiology. 2023-04-01 - 2 citationsOverall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).Pulak Goswami, Oladapo R Adeniran, Shelby K Frantz, Lea Matsuoka, Liping Du
BMC Gastroenterology. 2022-11-17
Press Mentions
ABK Biomedical Announces FDA IDE Stage 2 Approval for Route90, a Prospective, Multi-Center, Pivotal Study of Eye90 Microspheres® in Unresectable Hepatocellular CancerNovember 19th, 2024- ABK Biomedical Announces First Patient Treated in Its Multi-Center Pivotal Study of Eye90 Microspheres® in Hepatocellular CarcinomaOctober 25th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
